Michail Ignatiadis MD, PhD
Director of the Breast Medical Oncology Clinic & Program, Medical Oncology Department, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Brussels, BelgiumMichail Ignatiadis, MD, PhD, is the Director of the Breast Medical Oncology Clinic & Program, Medical Oncology Department, Jules Bordet Institute (IJB) and associate professor at the Université Libre de Bruxelles, Belgium. Since January 2021 is the chair of the breast cancer group of the EORTC. He is also leading the Academic Trials Promoting Team (ATPT) and he is member of the Executive and Research Boards of IJB since October 2016. From June 2018 to January 2021, he served in the Board of Directors of the EORTC as the chair of the clinical research division. He has been involved in many investigator initiated trials (IITs) sponsored by IJB at different stages of their development. He has been member of the Independent data monitoring committees for international trials and study chair of several IITs and industry sponsored trials.
Disclosures
Speaking fee/honoraria from Seattle Genetics, Daichi, AstraZeneca, Menarini/Stemline, Gilead Sciences, Rejuveron Senescence Therapeutics, and Novartis, grant/research support (to institution) from Pfizer, Roche, Inivata Inc, and Natera Inc and uncompensated roles for EORTC (EORTC Board of Directors 2018–2021, Chair EORTC Breast Cancer Group 2021–2024). meeting/travel grants from Roche, AstraZeneca, Gilead (all outside the submitted work).